Events
-
2025/08/26 Correctseq
CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical-stage biotechnology company pioneering transformer Base Editing (tBE) technology for the treatment of severe diseases, today announced the successful treatment of the first sickle cell disease (SCD) patient using its high-precision base-editing therapy CS-101.
-
2025/06/10 Correctseq
CorrectSequence Therapeutics to Participate in EHA2025 Congress
June 10, 2025, CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical stage biotechnology company aiming to use the innovative gene editing technology to help people with severe diseases, announced an oral presentation at the EHA2025 Congress, taking place June 12 – 15, 2025, in Milan, Italy.
-
2025/05/23 China Daily
China Daily | Chinese treatment cures Pakistani girl
A 4-year-old Pakistani girl with severe thalassemia has been successfully treated with a Chinese-developed gene-editing drug, marking the first time the technology has been used on a foreign minor, according to the Children's Hospital of Fudan University in Shanghai.
-
2025/05/21 SHINE
SHINE | Innovative treatment developed in China saves 4-year-old
A 4-year-old Pakistani girl with a serious blood disorder – thalassemia – has been cured by a China-developed innovative gene-editing technology, doctors at the Children's Hospital of Fudan University said on Tuesday.
-
2025/03/27 Correctseq
Precise and Efficient RNA Editing by Cleaving ADAR Inhibitor
Recently, a collaborative team led by Professor Chen Jia from the School of Life Science and Technology (SLST) at ShanghaiTech University and Professor Yang Li at Fudan University published a study titled “Specific and Efficient RNA A-to-I Editing through Cleavage of an ADAR Inhibitor”in Nature Biotechnology.
-
2025/03/27 Correctseq
An Efficient and Precise Mitochondrial Adenine Base Editor
Mitochondria, the “powerhouses” of cells, play a vital role in adenosine triphosphate (ATP) production. Mitochondria possess their own independent DNA, termed mitochondrial DNA (mtDNA), which encodes
-
2025/03/19 Correctseq
CorrectSequence Therapeutics’ CS-101 Successfully Treats Malaysian β-Thalassemia Patient
CorrectSequence Therapeutics Co., Ltd. (Correctseq) announced its self-developed base editing therapy, CS-101, has achieved another major milestone in the treatment of β-thalassemia. In collaboration with the First Affiliated Hospital of Guangxi Medical University, CS-101 has successfully treated the second overseas patient—a Malaysian individual with transfusion-dependent β-thalassemia. This milestone follows the first cure of a β-thalassemia overseas patient from Laos, marking another significant global achievement for the company
-
2024/12/10 SHINE
Locally-Developed Gene Editing Technology Cures Boy with Serious Blood Disorder
A 14-year-old boy with serious thalassemia has recovered due to a locally-developed innovative gene editing technology, the Children's Hospital of Fudan University said on Monday.